SAM
CRSP icon

Smartleaf Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Smartleaf Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1K Hold
321
– – ﹤0.01% 2067
2026
Q1 		$14.3K Buy
321
+5
+2% +$264 ﹤0.01% 2147
2025
Q4 		$16.8K Buy
316
+85
+37% +$5.09K ﹤0.01% 2128
2025
Q3 		$14.7K Buy
231
+51
+28% +$2.93K ﹤0.01% 1946
2025
Q2 		$8.55K Hold
180
– – ﹤0.01% 1878
2025
Q1 		$6.66K Hold
180
– – ﹤0.01% 2084
2024
Q4 		$6.96K Hold
180
– – ﹤0.01% 2138
2024
Q3 		$8.52K Buy
+180
New +$9.13K ﹤0.01% 1859

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Smartleaf Asset Management's CRSP Position: Q2 2026 in Review

Smartleaf Asset Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 321 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2067.

Smartleaf Asset Management first reported a position in CRSP in Q3 2024 and has held it in 8 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Smartleaf Asset Management held 321 shares of CRISPR Therapeutics worth $18.1K as of Q2 2026.
  • Smartleaf Asset Management left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #2067 holding.
  • Smartleaf Asset Management first reported a position in CRISPR Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.